Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | OXTR | P30559 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 2/20 | 0.44 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3247755 | 0.90 | MAPK1 (0.59) | MAPK1TSHRKMT2AF2TMPRSS6 | |
| SCHEMBL4867744 | 0.90 | MAPK1 (0.63) | MAPK1TSHROXTRKMT2AF2 | |
| SCHEMBL3254747 | 0.89 | MAPK1 (0.58) | MAPK1TSHROXTRKMT2AF2 | |
| SCHEMBL3250708 | 0.89 | MAPK1 (0.58) | MAPK1TSHRKMT2AF2TMPRSS6 | |
| SCHEMBL3265848 | 0.89 | MAPK1 (0.57) | MAPK1TSHROXTRKMT2AF2 | |
| SCHEMBL3252225 | 0.88 | MAPK1 (0.61) | MAPK1TSHROXTRKMT2AF2 | |
| SCHEMBL3256087 | 0.88 | MAPK1 (0.56) | MAPK1TSHRKMT2AF2TMPRSS6 | |
| SCHEMBL4870830 | 0.87 | MAPK1 (0.55) | MAPK1TSHRKMT2AALDH1A1NPSR1 | |
| SCHEMBL3254680 | 0.85 | MAPK1 (0.59) | MAPK1TSHROXTRKMT2AF2 | |
| SCHEMBL3250762 | 0.84 | MAPT (0.53) | MAPK1TSHRKMT2AF2TMPRSS6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7396958-B2 | Sulphonamide derivatives, their preparation and their therapeutic application | SANOFI AVENTIS (FR) | 2008-07-08 | — | — | US | disclosed |
| US-20070185136-A1 | SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185136-A1 | SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | HCRTR2, GIPR, SSTR2 | MAPK1 2674/4885TSHR 29/4885OXTR 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.